Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
Future Oncol
; 5(4): 421-32, 2009 May.
Article
in En
| MEDLINE
| ID: mdl-19450171
ABSTRACT
Angiogenesis, the process whereby tumors develop new blood vessels to facilitate growth and metastasis, is a pivotal event in tumorigenesis. It is tightly regulated by the VEGF system. Cediranib (AZD2171, Recentin; AstraZeneca, London, UK) is a novel and potent small-molecule inhibitor of VEGF signaling, with activity against the three VEGF receptors, as well as other targets. This article provides a comprehensive and up-to-date synopsis of all pertinent preclinical and clinical studies detailing this promising new therapy.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quinazolines
/
Angiogenesis Inhibitors
/
Neoplasms
Limits:
Animals
/
Humans
Language:
En
Journal:
Future Oncol
Year:
2009
Document type:
Article
Affiliation country:
United kingdom